Women who quit smoking and were treated with the GLP-1 receptor agonist dulaglutide were less likely to experience substantial weight gain compared with those who received placebo, according to ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

More Chinese adults with type 2 diabetes reduced their HbA1c to below 7% while not gaining weight or experiencing hypoglycemia when assigned dulaglutide vs. glimepiride or insulin glargine ...

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0 ...

The 40-week trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced new preclinical data showing the positive combined effects of its lead compound, buntanetap, with the GLP-1 agonist dulaglutide (Trulicity ...

Dulaglutide was FDA approved in 2014 for the treatment of adults with type 2 diabetes. Developer Eli Lilly announced in 2020 that the agent gained an indication to reduce the risk of major adverse ...

Full results of REWIND show dulaglutide significantly reduces CV events in patients with type 2 diabetes who primarily have CVD risk factors, rather than CVD itself. The major effect seems to be ...

Since 2014 dulaglutide has been approved alone or in combination with other drugs for the treatment of adults with type 2 diabetes. The German Institute for Quality and Efficiency in Health Care ...

RESEARCH DESIGN AND METHODS: This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5mg, dulaglutide 0.75mg, exenatide 10g, or ...

Dulaglutide injection should be given subcutaneously in the abdomen, thigh or upper arm once e every week at any time of the day. The initial dose is 0.75 mg once a week.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology ...